Summary & Overview
CPT 96105: Assessment of Aphasia and Cognitive Performance Testing
CPT code 96105 represents the assessment of aphasia and cognitive performance testing, a vital service in the evaluation of patients with neurological disorders impacting language and cognitive abilities. This code is widely recognized across the United States and is essential for clinicians such as neurologists, clinical neuropsychologists, and speech-language pathologists who diagnose and monitor conditions affecting the central nervous system.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, provide coverage for services billed under CPT code 96105. The publication offers a comprehensive overview of payer policies, clinical benchmarks, and recent policy updates relevant to this code. Readers will gain insights into the typical clinical scenarios where this assessment is utilized, the office-based nature of the service, and its role in the broader context of neurological and cognitive care.
Key topics include payer coverage details, common billing modifiers, associated provider taxonomies, and relevant ICD-10 diagnoses such as general paresis and various malignant neoplasms of the brain. The article also highlights related CPT codes and provides context for how 96105 fits within central nervous system assessment services. This summary equips healthcare professionals, billing specialists, and policy analysts with the information needed to understand the clinical and administrative landscape surrounding CPT code 96105.
CPT Code Overview
CPT code 96105 is used for the assessment of aphasia and cognitive performance testing. This procedure falls under the category of Central Nervous System Assessments/Tests and is typically performed in an office setting (Place of Service 11). The code is designed to capture the evaluation of language and cognitive abilities, which are critical for diagnosing and managing neurological conditions affecting communication and mental function.
Clinical & Coding Specifications
Clinical Context
A patient presents to the office with symptoms of language impairment following a neurological event, such as a stroke or brain tumor. The provider, often a speech-language pathologist, neurologist, or clinical neuropsychologist, conducts a structured assessment of aphasia and cognitive performance using standardized tools. The workflow includes patient history review, administration of cognitive and language tests, scoring, and interpretation. The results inform diagnosis, treatment planning, and documentation for payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
-
Modifier
52(Reduced Services): Used when the assessment is performed but not to its full extent, such as when the patient cannot complete all test components. -
Modifier
59(Distinct Procedural Service): Applied when the assessment is performed separately from other procedures, indicating it is distinct and not bundled.
| Provider Taxonomy Code | Specialty |
|---|---|
2084N0400X | Neurology Physician |
103G00000X | Clinical Neuropsychologist |
225X00000X | Speech-Language Pathologist |
Related Diagnoses
-
A52.17- General paresis- Relevant for patients with neurosyphilis presenting with cognitive and language deficits.
-
C71.0- Malignant neoplasm of cerebrum, except lobes and ventricles- Indicates a brain tumor affecting general cerebral function, potentially causing aphasia.
-
C71.1- Malignant neoplasm of frontal lobe- Tumors in the frontal lobe may impact language production and cognitive abilities.
-
C71.2- Malignant neoplasm of temporal lobe- Temporal lobe involvement can affect language comprehension and memory.
-
C71.3- Malignant neoplasm of parietal lobe- Parietal lobe tumors may disrupt language processing and spatial cognition.
-
C71.4- Malignant neoplasm of occipital lobe- Occipital lobe tumors are less commonly associated with aphasia but may affect visual processing.
-
C71.5- Malignant neoplasm of cerebral ventricle- Tumors in the ventricles can cause increased intracranial pressure and cognitive changes.
-
C71.6- Malignant neoplasm of cerebellum- Cerebellar tumors may impact coordination and, in rare cases, cognitive function.
-
C71.7- Malignant neoplasm of brain stem- Brain stem involvement can affect basic neurological functions and, indirectly, cognition.
-
C71.8- Malignant neoplasm of overlapping sites of brain- Tumors spanning multiple brain regions may cause complex cognitive and language deficits.
Related CPT Codes
96125- Assessment of cognitive performance testing
96125 is used for broader cognitive performance testing and may be performed alongside or as an alternative to 96105 when evaluating patients with neurological conditions. Both codes are relevant in assessing cognitive and language deficits, but 96105 specifically targets aphasia and related language impairments. These codes may be used together in complex cases requiring comprehensive evaluation.
National Reimbursement Benchmarks
Medicare's national mean rate for CPT code 96105 is $100.24, closely aligned with Aetna at $100.32. In contrast, the BUCA (average commercial) mean rate stands at $133.09, reflecting a substantial premium over Medicare. UnitedHealth Group and Cigna report the highest mean rates among major commercial payers, at $163.74 and $151.69 respectively.
Rate dispersion varies significantly across payers. Medicare exhibits the tightest range, with a difference of only $7.00 between its 75th and 25th percentiles. UnitedHealth Group shows the widest spread, with a $100.00 difference between its 75th and 25th percentiles, indicating greater variability in commercial reimbursement. Blue Cross Blue Shield and Cigna also display notable dispersion, at $47.50 and $82.00 respectively.
The table and chart below present a detailed breakdown of national mean rates and percentile values for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.